PMID- 1625093
OWN - NLM
STAT- MEDLINE
DCOM- 19920807
LR  - 20190630
IS  - 0022-3476 (Print)
IS  - 0022-3476 (Linking)
VI  - 121
IP  - 1
DP  - 1992 Jul
TI  - Human leukocyte antigen-DRB1*1104 in the chronic iridocyclitis of pauciarticular 
      juvenile rheumatoid arthritis.
PG  - 56-60
AB  - To determine whether genetic markers for chronic iridocyclitis could be 
      identified, we used both serologic and oligonucleotide dot blot techniques to 
      characterize immunogenetically 164 children with early-onset pauciarticular 
      juvenile rheumatoid arthritis. Seventy-eight children (47.6%) had chronic 
      iridocyclitis and 86 (52.4%) had not had evidence of eye disease during a mean 
      follow-up period after the onset of arthritis of 15.8 years (minimum of 5.5 
      years). Control subjects were 218 healthy, unrelated individuals. The analysis 
      was limited to alleles known to be associated with an increased or decreased risk 
      of early-onset pauciarticular juvenile rheumatoid arthritis or of chronic 
      iridocyclitis in this form of juvenile rheumatoid arthritis. Only one split of 
      human leukocyte antigen (HLA)-DR5, HLA-DRB1* 1104, showed a statistically 
      significant association with a risk of chronic iridocyclitis (chi-square value = 
      7.52; p = 0.036 adjusted; odds ratio 3.45); HLA-DQA1* 0501 and HLA-DQB1* 0301, 
      both in linkage disequilibrium with HLA-DRB1* 1104, also were significantly 
      associated with eye disease. Patients with both the DRB1* 1104 and DPB1* 0201 
      genes had a 7.7-fold increased risk for chronic iridocyclitis compared with that 
      for other patients. The presence of HLA-DRB1* 1104 was about four times as 
      specific, but only about one third as sensitive, as antinuclear antibodies in 
      identifying patients at risk for eye disease. Although all children with 
      early-onset pauciarticular juvenile rheumatoid arthritis should undergo periodic 
      slit-lamp examinations, those with the HLA class II gene DRB1* 1104 are at 
      particularly high risk for eye disease, and we recommend that they be monitored 
      carefully for its evolution.
FAU - Melin-Aldana, H
AU  - Melin-Aldana H
AD  - Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, Ohio 
      45229.
FAU - Giannini, E H
AU  - Giannini EH
FAU - Taylor, J
AU  - Taylor J
FAU - Lovell, D J
AU  - Lovell DJ
FAU - Levinson, J E
AU  - Levinson JE
FAU - Passo, M H
AU  - Passo MH
FAU - Ginsberg, J
AU  - Ginsberg J
FAU - Burke, M J
AU  - Burke MJ
FAU - Glass, D N
AU  - Glass DN
LA  - eng
GR  - AR21393/AR/NIAMS NIH HHS/United States
GR  - R01 AR39979/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (DNA Probes)
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Antibodies, Antinuclear/analysis
MH  - Arthritis, Juvenile/genetics/*immunology
MH  - Child
MH  - Chronic Disease
MH  - DNA Probes
MH  - Disease Susceptibility
MH  - Gene Amplification
MH  - Genes, MHC Class II/*genetics
MH  - Genetic Markers/genetics
MH  - Genotype
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DRB1 Chains
MH  - Haplotypes
MH  - Histocompatibility Antigens Class II/*genetics
MH  - Humans
MH  - Iridocyclitis/genetics/*immunology
MH  - Polymerase Chain Reaction
MH  - Risk Factors
MH  - Sensitivity and Specificity
EDAT- 1992/07/01 00:00
MHDA- 1992/07/01 00:01
CRDT- 1992/07/01 00:00
PHST- 1992/07/01 00:00 [pubmed]
PHST- 1992/07/01 00:01 [medline]
PHST- 1992/07/01 00:00 [entrez]
AID - S0022-3476(05)82541-7 [pii]
AID - 10.1016/s0022-3476(05)82541-7 [doi]
PST - ppublish
SO  - J Pediatr. 1992 Jul;121(1):56-60. doi: 10.1016/s0022-3476(05)82541-7.